Vertex Tumbles As It Stops Testing On Protein Deficiency TreatmentInvestors Business Daily • 10/14/20
Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR ModulatorsSeeking Alpha • 10/12/20
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of AgeBusiness Wire • 09/25/20